Jia Yao Holdings Limited Announces Entry into CBD Procurement and Export Business

Key Highlights and Investor Insights

• Strategic Business Expansion: Jia Yao Holdings Limited (“the Company”, HKEX: 01626) has officially commenced cannabidiol (CBD)-related business in April 2026, marking a significant move into the fast-growing health and biomedicine sector.
• Scope of Current Operations: The Group is primarily focused on the procurement and export of CBD from China, targeting clients in the skincare, daily chemical, and pharmaceutical industries across Europe and North America.
• Professional Operation Team: A specialized team with relevant industry experience has been established to manage and drive this new business segment.
• Full Legal Compliance: The Company adheres strictly to all applicable laws and regulations. It has secured all necessary qualifications, including:
  • Registration Certificate for Operation of Non-drug Precursor Chemicals
  • Export License for Dual-Use Items and Technologies

  These accreditations position Jia Yao Holdings as one of the few enterprises in China legally authorized to conduct CBD procurement and export activities.

• Business Progress and Revenue Generation: Although still in the early stages, the Group has already signed substantive trade contracts and generated actual sales revenue and collections from the CBD business.
• Expansion and R&D Plans: The Group aims to leverage its supply chain advantages to compete globally on price and expand into downstream terminal products, such as beauty, personal care, and pet healthcare. There are also plans to pursue R&D collaborations with academic institutions to further enhance the product pipeline.
• Market Outlook: With increasing global recognition of the medical value of CBD and regulatory relaxations in several countries, significant market growth is anticipated. The Company expects this new business to positively contribute to future cash flow and profit growth.

Shareholder Information and Potential Impact on Share Value

Why This Matters: This strategic entry into the CBD sector is a potentially price-sensitive development for Jia Yao Holdings Limited. Investors should note:

• The Company is among the first-movers in China with full legal compliance in the CBD export space, which could translate into a competitive advantage and early-mover benefits.
• Early contracts and revenue generation validate the market demand and operational capability of the Group in this new field, suggesting early-stage de-risking of the business model.
• Plans for downstream expansion and enhanced R&D signal a long-term commitment and potential for value-added products, which could further boost margins and market share.
• Given the positive regulatory trends and confirmed medical value of CBD internationally, the sector is expected to see sustained growth, potentially supporting share price appreciation if execution is successful.

Board Composition (as of April 21, 2026)

• Chairman and Executive Director: Yang Yoong An
• Executive Director: Li Lin
• Non-Executive Director: Yang Fan
• Independent Non-Executive Directors: Gong Jinjun, Guo Wei, Wang Ping

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research or consult with professional advisors before making investment decisions. The information provided is based on company disclosures as of April 21, 2026, and may be subject to change.

View JIA YAO HLDGS Historical chart here